2023-10-31 18:59:39
Home Health
Only doctors competent in oncology will be able to prescribe it and particular attention will be paid to monitoring side effects.
Published on 10/31/2023 7:59 p.m. Updated on 10/31/2023 8:27 p.m.
Reading time: 1 min Jemperli is developed by the pharmaceutical laboratory GSK. (JEAN-FRANCOIS MONIER / AFP)
An announcement that raises hope for thousands of patients. The French health authorities announced on Tuesday October 31 that they had approved, according to a so-called early access procedure, a treatment developed by the British giant GSK once morest endometrial cancer. “Since October 23, the drug Jemperli, created from the molecule dostarlimab, has been available in early access for women with newly diagnosed or recurrent advanced endometrial cancer”writes the National Medicines Safety Agency (ANSM).
Jemperli, which must be administered in conjunction with chemotherapy, has already been approved by other health authorities to treat this cancer, notably in the United States at the end of the summer. A file is currently being examined by the European Union medicines authority, the EMA, but it has not yet made a decision. The ANSM therefore authorized this drug before the European green light, even if it does so by limiting for the moment the prescription conditions according to the early access procedure. Only doctors competent in oncology will be able to prescribe it and particular attention will be paid to monitoring side effects.
Endometrial cancer, which usually affects women following menopause, develops in the inner lining of the uterus, known as the endometrium. It is one of the most common cancers, with nearly 10,000 cases per year in France. Although it has a relatively good prognosis compared to other female cancers, such as cervical cancer, it remains the cause of many deaths.
View comments
1698799973
#treatment #approved #France
